CORREAL GARRISON: Open Payments
NPI 1427421528 · NEW ALBANY, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,661 in 110 payments from 25 companies in 2025. Trend: 2023 $2,203 · 2024 $1,730 · 2025 $1,661
Food & beverage: $1,661
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $208 |
| AstraZeneca Pharmaceuticals LP | 10 | $206 |
| PFIZER INC. | 15 | $166 |
| Otsuka America Pharmaceutical, Inc. | 10 | $159 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $155 |
| Novo Nordisk Inc | 14 | $151 |
| Abbott Laboratories | 4 | $82 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $80 |
| Ardelyx, Inc. | 2 | $48 |
| Amgen Inc. | 3 | $45 |
Products named: REXULTI, CAPLYTA, NURTEC ODT, AIRSUPRA, FARXIGA, Ozempic, Kerendia, UBRELVY.
Industry payments across MS — which companies pay providers there.
